By physician referral or invitation only

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

The overall study objective is to determine the ability to achieve treatment free remission (TFR) in pediatric patients who discontinue their Tyrosine kinase inhibitor and to describe the effect of treatment free remission on quality of life measures and long term effects.

Age & Gender

5 years ~ 24.99 years
Male, Female, Gender Inclusive

Contact the Team

Location

Thank you for your interest, but this study is recruiting by invitation only.

United States (Nationwide)

Additional Study Information

Principal Investigator

Thomas Alexander
Pediatrics - Hematology/Oncology

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Pediatric Cancers, Leukemia)
Child and Teen Health

IRB Number

21-0111

ClinicalTrials.gov

NCT03817398

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.